Streetbeat News

Stock Prices

TREE

LendingTree (NASDAQ:TREE) has received mixed analyst ratings over the past quarter, with 3 bullish and 2 somewhat bullish ratings. Analysts have raised their 12-month price targets, with the average target now at $56.4, marking a 26.46% increase from the previous average. Despite positive analyst sentiment, LendingTree faces financial challenges, including declining revenue, low net margin, and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

June 20, 2024 | 12:00 pm

ADIL

Adial Pharmaceuticals announced the publication of Phase 3 ONWARD study results in the European Journal of Internal Medicine, showing the efficacy of AD04 in reducing heavy drinking days among patients with specific genetic profiles. The study found minimal adverse events and high compliance, suggesting a promising treatment for alcohol use disorder.

Portfolio Pulse from Vandana Singh

June 20, 2024 | 12:00 pm

GMAB

Analysts' ratings for Genmab (NASDAQ:GMAB) over the last quarter show a mix of bullish and bearish sentiments. The average 12-month price target is $48.5, with a high of $53.00 and a low of $32.00. Genmab has shown strong financial performance with significant revenue growth and profitability.

Portfolio Pulse from Benzinga Insights

June 20, 2024 | 12:00 pm

ABR

Analysts have mixed views on Arbor Realty Trust (NYSE:ABR) with recent ratings showing 1 somewhat bullish, 3 indifferent, and 1 somewhat bearish. The average 12-month price target is $13.45, down 7.88% from the prior average. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance.

Portfolio Pulse from Benzinga Insights

June 20, 2024 | 12:00 pm

PTN

Palatin Technologies has initiated a Phase 2 study of Bremelanotide, co-administered with a Phosphodiesterase 5 inhibitor, for erectile dysfunction in patients unresponsive to PDE5i monotherapy. Topline data is expected soon.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 11:59 am

CCG

Cheche Group shares are trading higher following the announcement of a partnership with NIO Insurance Broker.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 11:59 am

CMND

Clearmind Medicine shares are trading higher following the announcement of an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 11:59 am

TRVN

Trevena shares are trading higher after the company announced promising preclinical data for TRV045, showing long-term analgesic effects in a neuropathic pain model. Additionally, TRV045 results have led to further NIH-initiated studies in epilepsy prevention and treatment.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 11:56 am

JAZZ

Jazz Pharmaceuticals' Suvecaltamide (JZP385) did not achieve statistical significance at 30mg versus placebo on the primary endpoint of change from baseline to week 12 on the Essential Tremor Rating Assessment Scale Modified Composite Outcome Score. The trial also did not meet the key secondary endpoint of the Clinical Global Impression-severity Scale.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 11:56 am

TPST

Tempest Therapeutics shares are trading higher after the company announced that the TPST-1120 arm improved all efficacy endpoints compared to the standard of care (SoC) control in a study.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 11:54 am